SCHEMBL19670572

SCHEMBL19670572

CCN1CCCN(C(=O)Nc2cccc(CNC(=O)CCCCCN)c2)c2nc(-c3cccc(C(F)(F)F)c3)ccc21

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.35
▸ CA2 P00918 1/20 0.35
▸ CA9 Q16790 1/20 0.35
▸ MAPT P10636 2/20 0.35
▸ HDAC3 O15379 2/20 0.35
▸ HDAC1 Q13547 2/20 0.35
▸ HDAC2 Q92769 2/20 0.35
▸ HDAC10 Q969S8 2/20 0.35
▸ HDAC8 Q9BY41 2/20 0.35
▸ HDAC6 Q9UBN7 2/20 0.35
▸ HDAC11 Q96DB2 1/20 0.35
▸ NCOR2 Q9Y618 1/20 0.35
▸ BACE1 P56817 1/20 0.34
▸ USP2 O75604 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ RIPK1 Q13546 1/20 0.34
▸ EPHB4 P54760 2/20 0.34
▸ NPC1 O15118 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ KMT2A Q03164 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19670361 0.88 HDAC3 (0.40) HDAC3HDAC1HDAC2HDAC10HDAC8
SCHEMBL16785533 0.85 CA2 (0.37) CA2CA9HDAC3HDAC1HDAC2
SCHEMBL19670249 0.83 CA2 (0.42) LMNACA2CA9HDAC1BACE1
SCHEMBL19365865 0.83 TSHR (0.36) CA2CA9MAPTHDAC3HDAC1
SCHEMBL19865035 0.82 CA2 (0.37) LMNACA2CA9MAPTBACE1
SCHEMBL16785535 0.81 EPHX2 (0.38) LMNACA2CA9HDAC3HDAC1
SCHEMBL19365694 0.81 CHRM3 (0.45) MAPTKMT2A
SCHEMBL19365749 0.81 CA2 (0.42) LMNACA2CA9MAPTPOLB
SCHEMBL17624535 0.81 KDM4E (0.39) LMNACA2CA9MAPTUSP2
SCHEMBL19670574 0.81 KDM4E (0.39) LMNACA2CA9MAPTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2020-03-17 — — US disclosed
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS GLAXOSMITHKLINE LLC 2017-12-14 — — US disclosed
US-9834558-B2 Substituted bridged urea analogs as sirtuin modulators GLAXOSMITHKLINE LLC (US) 2017-12-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170355697-A1 SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS SIRT1, SIRT3, SIRT2 LMNA 3617/4885CA2 4253/4885CA9 4248/4885
US-10590135-B2 Substituted bridged urea analogs as sirtuin modulators SIRT1, SIRT3, SIRT2 LMNA 3617/4885CA2 4253/4885CA9 4248/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback